Palo Alto, CA — Julian Wolf M.D., postdoctoral fellow in the Mahajan Lab, graduated with the first class of Stanford’s Master of Science in Translational Research and Applied Medicine (M-TRAM) Program.
Nobel Laureate and Stanford Professor Carolyn Bertozzi Ph.D. gave the keynote and her congratulations to Julian.
The aim of the M-TRAM Program is to give graduates the tools to use translational medical research, bioengineering, and medical technology to develop novel drug therapeutics, molecular diagnostics, immunotherapies, gene therapies, cell therapies, vaccines, and medical devices.
Vinit Mahajan M.D., Ph.D., Stanford professor and vice chair of ophthalmology research, said, “When I learned about the M-TRAM Program, I knew Julian would be a perfect fit. His background as an ophthalmologist and expertise in bioinformatics was a great foundation. His work over the last year integrating transcriptomics and proteomics, along with artificial intelligence, has taken human eye disease biomarkers to another level.”
One of the end goals of the Mahajan Lab is to take bench science and turn it into effective therapies for hard-to-treat eye diseases. The M-TRAM Program is closely aligned with this philosophy of science. The team has spent years developing collaborations to promote translational research to better care for patients. Julian has been a major player in this effort.
Julian said, “In a highly collaborative environment involving clinician-scientists, biologists, computer scientists, and entrepreneurs, I learned to combine cutting-edge molecular technology, systems biology, and artificial intelligence to identify new therapies for human disease. I learned from world-class researchers, industry leaders, and successful entrepreneurs how my scientific discoveries in the laboratory could one day improve my patients' lives.”
Dean Felsher M.D., Ph.D., director of the M-Tram Program, has capitalized on Stanford’s rich scientific and entrepreneurial environment to create a unique one-year experience for academic and industry leaders to successfully turn scientific discoveries into clinical therapies.
Mahajan said, “Stanford is a special place that encourages researchers to pursue an idea from its inception all the way to biomedical development. The M-TRAM curriculum and faculty list is amazing, and I am very proud Julian and I were part of this impactful Stanford program.”